Template:Antidepressants: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 22:51, 12 April 2017 view source2602:306:bd5e:1390:a916:107d:414f:30e3 (talk)No edit summary← Previous edit		Latest revision as of 08:47, 30 September 2023 view source Yellow whisper (talk \| contribs)18 editsmNo edit summary
(20 intermediate revisions by 12 users not shown)
Line 8:		Line 8:
	\| state1 = uncollapsed		\| state1 = uncollapsed
	\| group1 = Specific ]s and/or ]s		\| group1 = Specific ]s and/or ]s
	\| list1 = {{Navbox subgroup		\| list1 = {{Navbox\|subgroup

	\| group1 = ]s		\| group1 = {{abbrlink\|SSRIs\|Selective serotonin reuptake inhibitors}}
	\| list1 =		\| list1 =
	* ]		* ]
Line 21:		Line 21:
	* ]<sup>‡</sup>		* ]<sup>‡</sup>

	\| group2 = ]s		\| group2 = {{abbrlink\|SNRIs\|Serotonin–norepinephrine reuptake inhibitors}}
	\| list2 =		\| list2 =
	* ]		* ]
Line 30:		Line 30:
	* ]		* ]

	\| group3 = ]s		\| group3 = {{abbrlink\|NRIs\|Norepinephrine reuptake inhibitors}}
	\| list3 =		\| list3 =
	* ]		* ]
Line 36:		Line 36:
	* ]		* ]

	\| group4 = ]s		\| group4 = {{abbrlink\|NDRIs\|Norepinephrine–dopamine reuptake inhibitors}}
	\| list4 =		\| list4 =
	* ]<sup>‡</sup>		* ]<sup>‡</sup>
			* ]
	* ]<sup>‡</sup>		* ]<sup>‡</sup>

	\| group5 = ]s		\| group5 = {{abbrlink\|NaSSAs\|Noradrenergic and specific serotonergic antidepressants}}
	\| list5 =		\| list5 =
	* ]		* ]
Line 47:		Line 48:
	* ]		* ]

	\| group6 = ]s		\| group6 = {{abbrlink\|SARIs\|Serotonin antagonist and reuptake inhibitors}}
	\| list6 =		\| list6 =
	* ]		* ]
Line 53:		Line 54:
	* ]		* ]

	\| group7 = ]s		\| group7 = {{abbrlink\|SMS\|Serotonin modulator and stimulators}}
	\| list7 =		\| list7 =
	* ]		* ]
Line 62:		Line 63:
	* ]		* ]
	* ]		* ]
			* ]
	* ]<!--NRI, nAChR antagonist; not a significant DRI-->
	* ]		* ]
	* ]<sup>‡</sup>		* ]<sup>‡</sup>
			* ]
	* ]		* ]
	* ]		* ]
			* ]<sup>§</sup>
	* ]<sup>‡</sup>		* ]<sup>‡</sup>
	* ]<sup>‡</sup>		* ]<sup>‡</sup>
	* ]<sup>‡</sup>		* ]<sup>‡</sup>
			* ]<sup>‡</sup>
			* ]
	* ]		* ]
	* ]		* ]
Line 77:		Line 82:
	\| state2 = uncollapsed		\| state2 = uncollapsed
	\| group2 = ] and ]s		\| group2 = ] and ]s
	\| list2 = {{Navbox subgroup		\| list2 = {{Navbox\|subgroup

	\| group1 = ]s		\| group1 = {{abbrlink\|TCAs\|Tricyclic antidepressants}}
	\| list1 =		\| list1 =
	* ]<sup>‡</sup>		* ]<sup>‡</sup>
	* ]<sup>#</sup>		* ]<sup>#</sup>
	* ]		* ]
		⚫	* ]
	* ]<sup>‡</sup>		* ]<sup>‡</sup>
	* ]<sup>#</sup>		* ]<sup>#</sup>
Line 109:		Line 115:
	* ]		* ]

	\| group2 = ]s		\| group2 = {{abbrlink\|TeCAs\|Tetracyclic antidepressants}}
	\| list2 =		\| list2 =

⚫	* ]
	* ]		* ]
	* ]		* ]
Line 125:		Line 131:
	\| state3 = uncollapsed		\| state3 = uncollapsed
	\| group3 = ]s		\| group3 = ]s
	\| list3 = {{Navbox subgroup		\| list3 = {{Navbox\|subgroup

	\| group1 = Non-selective		\| group1 = Non-selective
Line 148:		Line 154:
	* ''Reversible:'' ]<sup>‡</sup>		* ''Reversible:'' ]<sup>‡</sup>

			* ''Mixed:'' ]
⚫	\| group2 = MAO<sub>A</sub>-selective

		⚫	\| group2 = {{abbrlink\|MAO<sub>A</sub>\|Monoamine oxidase A}}-selective
	\| list2 =		\| list2 =

	* ''Reversible:'' ]		* ''Reversible:'' ]
	* ]
	* ]		* ]
	* ]<sup>‡</sup>		* ]<sup>‡</sup>
Line 160:		Line 167:
	* ]		* ]

	\| group3 = MAO<sub>B</sub>-~~Selective~~		\| group3 = {{abbrlink\|MAO<sub>B</sub>\|Monoamine oxidase B}}-selective
	\| list3 =		\| list3 =
	* ''Irreversible:'' ]		* ''Irreversible:'' ]
Line 169:		Line 176:
	\| group4 = ]		\| group4 = ]
	\| list4 =		\| list4 =
	* ]s (], ], ], ])		* ]s (], ], ], ], ], ])
			* ]
	* ]s (], ])
	* ] (], ])		* ] (], ])
	* ]s (] (T<sub>3</sub>), ] (T<sub>4</sub>))		* ]s (] (T<sub>3</sub>), ] (T<sub>4</sub>))
Line 177:		Line 184:
	\| group5 = Miscellaneous		\| group5 = Miscellaneous
	\| list5 =		\| list5 =
	* ]		* ]
			* ] ]s (], ])
	* ]		* ]
	* ]		* ]
	* ]		* ]
	* ]		* ]

Latest revision as of 08:47, 30 September 2023

Antidepressants (N06A)

Specific reuptake inhibitors and/or receptor modulators

SSRIsTooltip Selective serotonin reuptake inhibitors	Citalopram Escitalopram Fluoxetine Fluvoxamine Indalpine Paroxetine Sertraline Zimelidine
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors	Desvenlafaxine Duloxetine Levomilnacipran Milnacipran Tofenacin Venlafaxine
NRIsTooltip Norepinephrine reuptake inhibitors	Atomoxetine Reboxetine Viloxazine
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors	Amineptine Bupropion Nomifensine
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants	Mianserin Mirtazapine Setiptiline
SARIsTooltip Serotonin antagonist and reuptake inhibitors	Etoperidone Nefazodone Trazodone
SMSTooltip Serotonin modulator and stimulators	Vilazodone Vortioxetine
Others	Agomelatine Amisulpride Dextromethorphan/bupropion Esketamine Etryptamine Gepirone Indeloxazine Flupentixol Ketamine Medifoxamine Metryptamine Oxaflozane Pivagabine Tandospirone Teniloxazine Tianeptine

Tricyclic and tetracyclic antidepressants

TCAsTooltip Tricyclic antidepressants	Amineptine Amitriptyline Amitriptylinoxide Amoxapine Butriptyline Clomipramine Demexiptiline Desipramine Dibenzepin Dimetacrine Dosulepin Doxepin Imipramine Imipraminoxide Iprindole Lofepramine Melitracen Metapramine Nitroxazepine Nortriptyline Noxiptiline Opipramol Pipofezine Propizepine Protriptyline Quinupramine Tianeptine Trimipramine
TeCAsTooltip Tetracyclic antidepressants	Maprotiline Mianserin Mirtazapine Setiptiline
Others	Tiazesim

Monoamine oxidase inhibitors

Non-selective

Reversible: Caroxazone

Mixed: Bifemelane

MAO_ATooltip Monoamine oxidase A-selective

MAO_BTooltip Monoamine oxidase B-selective

Irreversible: Selegiline

Adjunctive therapies
Atypical antipsychotics (aripiprazole, brexpiprazole, lurasidone, olanzapine, quetiapine, risperidone) Buspirone Lithium (lithium carbonate, lithium citrate) Thyroid hormones (triiodothyronine (T₃), levothyroxine (T₄))

Miscellaneous
Ademetionine (SAMe) GABAkine neurosteroids (brexanolone, zuranolone) Hypericum perforatum (St. John's Wort) Oxitriptan (5-HTP) Rubidium chloride (RbCl) Tryptophan

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

Categories: